BACKGROUND: The study aimed to identify factors associated with less-than-optimal radiotherapy (RT) and its impact on disease-free survival in women aged 66+ years diagnosed with stage I breast cancer or ductal carcinoma in situ (DCIS). METHODS: The subjects were women diagnosed from 1991 to 1999 in the linked Surveillance, Epidemiology, and End Results (SEER)-Medicare database who underwent breast-conserving surgery and RT within 12 months postdiagnosis. The authors conducted descriptive and multivariate survival analyses, and considered age, race, poverty, marital status, comorbidity indices, rural/urban, radiation oncologist density, comedo necrosis histology (DCIS only), chemotherapy receipt (stage I only), and RT completion (3+ weeks of treatment) and delay (8+ weeks postsurgery without chemotherapy; 4+ weeks postchemotherapy). RESULTS: Of 7791 subjects, 16% experienced RT delay, and 3% had incomplete RT. Subjects with stage I disease who were more likely to delay RT were of black race (odds ratio [OR], 1.56; 95% confidence interval [CI], 1.17-2.08), whereas women in areas of high radiation oncologist density were less likely to delay (OR, 0.73; 95% CI, 0.66-0.81). Those living in high poverty areas were less likely to complete RT (P < .03), as were those undergoing chemotherapy (OR, 1.82; 95% CI, 1.15-2.88). Stage I breast cancer patients with delayed RT were more likely to experience a subsequent breast event (OR, 1.14; 95% CI, 1.00-1.30), and those with incomplete RT had a higher rate of overall mortality (OR, 1.32; 95% CI, 1.06-1.63). Factors associated with lower subsequent breast events included older age, lower poverty, and being married. RT delays of 12+ weeks (or 8+ weeks postchemotherapy) had a strongly negative impact on subsequent events (OR, 3.94; 95% CI, 2.51-6.17 for DCIS; OR, 2.77; 95% CI, 1.84-2.59 for stage I). CONCLUSIONS: RT should be facilitated to ensure completion and timeliness, especially for early invasive breast cancer patients. (c) 2008 American Cancer Society
BACKGROUND: The study aimed to identify factors associated with less-than-optimal radiotherapy (RT) and its impact on disease-free survival in women aged 66+ years diagnosed with stage I breast cancer or ductal carcinoma in situ (DCIS). METHODS: The subjects were women diagnosed from 1991 to 1999 in the linked Surveillance, Epidemiology, and End Results (SEER)-Medicare database who underwent breast-conserving surgery and RT within 12 months postdiagnosis. The authors conducted descriptive and multivariate survival analyses, and considered age, race, poverty, marital status, comorbidity indices, rural/urban, radiation oncologist density, comedo necrosis histology (DCIS only), chemotherapy receipt (stage I only), and RT completion (3+ weeks of treatment) and delay (8+ weeks postsurgery without chemotherapy; 4+ weeks postchemotherapy). RESULTS: Of 7791 subjects, 16% experienced RT delay, and 3% had incomplete RT. Subjects with stage I disease who were more likely to delay RT were of black race (odds ratio [OR], 1.56; 95% confidence interval [CI], 1.17-2.08), whereas women in areas of high radiation oncologist density were less likely to delay (OR, 0.73; 95% CI, 0.66-0.81). Those living in high poverty areas were less likely to complete RT (P < .03), as were those undergoing chemotherapy (OR, 1.82; 95% CI, 1.15-2.88). Stage I breast cancerpatients with delayed RT were more likely to experience a subsequent breast event (OR, 1.14; 95% CI, 1.00-1.30), and those with incomplete RT had a higher rate of overall mortality (OR, 1.32; 95% CI, 1.06-1.63). Factors associated with lower subsequent breast events included older age, lower poverty, and being married. RT delays of 12+ weeks (or 8+ weeks postchemotherapy) had a strongly negative impact on subsequent events (OR, 3.94; 95% CI, 2.51-6.17 for DCIS; OR, 2.77; 95% CI, 1.84-2.59 for stage I). CONCLUSIONS: RT should be facilitated to ensure completion and timeliness, especially for early invasive breast cancerpatients. (c) 2008 American Cancer Society
Authors: Danielle S Bitterman; David Grew; Ping Gu; Richard F Cohen; Nicholas J Sanfilippo; Cynthia G Leichman; Lawrence P Leichman; Harvey G Moore; Heather T Gold; Kevin L Du Journal: J Gastrointest Oncol Date: 2015-10
Authors: Grace L Smith; Jinhai Huo; Sharon H Giordano; Kelly K Hunt; Thomas A Buchholz; Benjamin D Smith Journal: Int J Radiat Oncol Biol Phys Date: 2015-05-14 Impact factor: 7.038
Authors: Marquita W Lewis-Thames; Leslie R Carnahan; Aimee S James; Karriem S Watson; Yamilé Molina Journal: J Rural Health Date: 2020-01-11 Impact factor: 4.333
Authors: Kyle Freischlag; Zhifei Sun; Mohamed A Adam; Jina Kim; Manisha Palta; Brian G Czito; John Migaly; Christopher R Mantyh Journal: JAMA Surg Date: 2017-06-01 Impact factor: 14.766
Authors: Heather Taffet Gold; Melony E S Sorbero; Jennifer J Griggs; Huong T Do; Andrew W Dick Journal: Med Care Res Rev Date: 2011-05-19 Impact factor: 3.929
Authors: Harriet Eldredge-Hindy; Jianmin Pan; Shesh N Rai; Leonid B Reshko; Anthony Dragun; Elizabeth C Riley; Kelly M McMasters; Nicolas Ajkay Journal: Ann Surg Oncol Date: 2021-03-18 Impact factor: 5.344
Authors: Alok Kapoor; Tracy A Battaglia; Alexis P Isabelle; Amresh D Hanchate; Richard L Kalish; Sharon Bak; Rebecca G Mishuris; Swati M Shroff; Karen M Freund Journal: J Health Care Poor Underserved Date: 2014-02
Authors: Tracy A Battaglia; M Christina Santana; Sharon Bak; Manjusha Gokhale; Timothy L Lash; Arlene S Ash; Richard Kalish; Stephen Tringale; James O Taylor; Karen M Freund Journal: Cancer Date: 2010-02-15 Impact factor: 6.860